NASDAQ:BPMC - Blueprint Medicines Stock Price, Forecast & News

Blueprint Medicines' stock was trading at $52.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BPMC stock has increased by 10.9% and is now trading at $58.11. View which stocks have been mosted impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 1 hold rating, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Blueprint Medicines.

Blueprint Medicines is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Blueprint Medicines.

Blueprint Medicines Corp (NASDAQ:BPMC) posted its quarterly earnings data on Thursday, February, 13th. The biotechnology company reported ($1.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.71) by $0.36. The biotechnology company earned $51.53 million during the quarter, compared to analyst estimates of $26 million. Blueprint Medicines had a negative net margin of 522.75% and a negative return on equity of 72.52%. The business's revenue was up 4888.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.83) EPS. View Blueprint Medicines' earnings history.

13 Wall Street analysts have issued 12 month target prices for Blueprint Medicines' shares. Their forecasts range from $70.00 to $125.00. On average, they anticipate Blueprint Medicines' stock price to reach $105.75 in the next twelve months. This suggests a possible upside of 82.0% from the stock's current price. View analysts' price targets for Blueprint Medicines.

Media headlines about BPMC stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Blueprint Medicines earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutBlueprint Medicines.

Blueprint Medicines saw a increase in short interest in February. As of February 28th, there was short interest totaling 2,920,000 shares, an increase of 8.6% from the February 13th total of 2,690,000 shares. Based on an average daily trading volume, of 747,600 shares, the days-to-cover ratio is currently 3.9 days. Approximately 7.0% of the shares of the company are sold short. View Blueprint Medicines' Current Options Chain.

Some companies that are related to Blueprint Medicines include Merck KGaA (MKGAF), Genmab A/S (GNMSF), GALAPAGOS NV/S (GLPG), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Beigene (BGNE), Mylan (MYL), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO) and ACADIA Pharmaceuticals (ACAD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), Amarin (AMRN), Micron Technology (MU), Crispr Therapeutics (CRSP), Nektar Therapeutics (NKTR), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), AbbVie (ABBV), Agile Therapeutics (AGRX) and Intercept Pharmaceuticals (ICPT).

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Blueprint Medicines' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Cadian Capital Management LP (4.00%), State Street Corp (3.81%), Alliancebernstein L.P. (2.08%), Norges Bank (1.85%) and Westfield Capital Management Co. LP (1.57%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View institutional ownership trends for Blueprint Medicines.

BPMC stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Pictet Asset Management Ltd., Perceptive Advisors LLC, BVF Inc. IL, Macquarie Group Ltd., Macquarie Group Ltd., Victory Capital Management Inc., and Westfield Capital Management Co. LP. Company insiders that have sold Blueprint Medicines company stock in the last year include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch, and Nicholas Lydon. View insider buying and selling activity for Blueprint Medicines.

BPMC stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Cadian Capital Management LP, Point72 Asset Management L.P., Candriam Luxembourg S.C.A., Credit Suisse AG, Barclays PLC, Alliancebernstein L.P., and Jane Street Group LLC. View insider buying and selling activity for Blueprint Medicines.

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BPMC stock can currently be purchased for approximately $58.11.

Blueprint Medicines has a market capitalization of $3.14 billion and generates $66.51 million in revenue each year. The biotechnology company earns $-347,690,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe. View additional information about Blueprint Medicines.

The official website for Blueprint Medicines is http://www.blueprintmedicines.com/.

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]